These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12632315)

  • 1. [Heroin-assisted treatment of opioid addicts in Switzerland from 1994-2001--utilisation and characteristics of admissions and discharges].
    Gschwend P; Rehm J; Eschmann S; Uchtenhagen A
    Gesundheitswesen; 2003 Feb; 65(2):75-80. PubMed ID: 12632315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study.
    Rehm J; Gschwend P; Steffen T; Gutzwiller F; Dobler-Mikola A; Uchtenhagen A
    Lancet; 2001 Oct; 358(9291):1417-23. PubMed ID: 11705488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in heroin-assisted treatment in Switzerland 1994-2000.
    Rehm J; Frick U; Hartwig C; Gutzwiller F; Gschwend P; Uchtenhagen A
    Drug Alcohol Depend; 2005 Aug; 79(2):137-43. PubMed ID: 16002023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors from a long-term follow-up of heroin-assisted treatment in Switzerland 1994-2007].
    Frick U; Wiedermann W; Schaub M; Uchtenhagen A; Rehm J
    Psychiatr Prax; 2010 May; 37(4):175-82. PubMed ID: 20148381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of opiate users leaving detoxification treatment against medical advice.
    Kenne DR; Boros AP; Fischbein RL
    J Addict Dis; 2010 Jul; 29(3):383-94. PubMed ID: 20635287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage regimes in the prescription of heroin and other narcotics to chronic opioid addicts in Switzerland--Swiss national cohort study.
    Gschwend P; Rehm J; Blättler R; Steffen T; Seidenberg A; Christen S; Bürki C; Gutzwiller F
    Eur Addict Res; 2004; 10(1):41-8. PubMed ID: 14665805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heroin-assisted treatment in Switzerland: a case study in policy change.
    Uchtenhagen A
    Addiction; 2010 Jan; 105(1):29-37. PubMed ID: 19922519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a monitoring system for heroin-assisted substitution treatment in Switzerland.
    Gschwend P; Rehm J; Lezzi S; Blättler R; Steffen T; Gutzwiller F; Uchtenhagen A
    Soz Praventivmed; 2002; 47(1):33-8. PubMed ID: 12050928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up.
    Güttinger F; Gschwend P; Schulte B; Rehm J; Uchtenhagen A
    Eur Addict Res; 2003 Apr; 9(2):73-9. PubMed ID: 12644733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Co-morbidity: psychiatric disorder of opiate addicts at entry into heroin-assisted treatment].
    Frei A; Rehm J;
    Psychiatr Prax; 2002 Jul; 29(5):251-7. PubMed ID: 12101491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of skin diseases in intravenous drug dependent patients treated with heroin substitution].
    Conrad C; Steffen T; Gutzwiller F
    Praxis (Bern 1994); 2000 Nov; 89(46):1899-906. PubMed ID: 11111408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating incidence trends in regular heroin use in 26 regions of Switzerland using methadone treatment data.
    Nordt C; Landolt K; Stohler R
    Subst Abuse Treat Prev Policy; 2009 Jun; 4():14. PubMed ID: 19519920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEdeTTE, a longitudinal study on effectiveness of treatments for heroin addiction in Italy: study protocol and characteristics of study population.
    Bargagli AM; Faggiano F; Amato L; Salamina G; Davoli M; Mathis F; Cuomo L; Schifano P; Burroni P; Perucci CA;
    Subst Use Misuse; 2006; 41(14):1861-79. PubMed ID: 17162594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of methadone patients' lengths of stay for first and second admissions.
    Steer RA; Kotzker E
    Drug Alcohol Depend; 1978 Nov; 3(6):399-403. PubMed ID: 720210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17.
    Jones CM; Underwood N; Compton WM
    Addiction; 2020 Feb; 115(2):347-353. PubMed ID: 31503384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [8 years experience with heroin-assited treatment in Switzerland--current results and future improvements].
    Gschwend P; Eschmann S; Güttinger F; Hosek M; Rehm J; Uchtenhagen A
    Ther Umsch; 2003 Jun; 60(6):355-60. PubMed ID: 12848072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends of heroin use and heroin injection epidemics in Europe: findings from the EMCDDA treatment demand indicator (TDI).
    Barrio G; Montanari L; Bravo MJ; Guarita B; de la Fuente L; Pulido J; Vicente J
    J Subst Abuse Treat; 2013 Jul; 45(1):19-30. PubMed ID: 23462151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification.
    San L; Tato J; Torrens M; Castillo C; Farré M; Camí J
    Drug Alcohol Depend; 1993 May; 32(3):281-6. PubMed ID: 8102333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice variation and length of stay in alcohol and drug detoxification centers.
    Jonkman JN; McCarty D; Harwood HJ; Normand SL; Caspi Y
    J Subst Abuse Treat; 2005 Jan; 28(1):11-8. PubMed ID: 15723727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of benzodiazepine use on methadone maintenance treatment outcomes.
    Brands B; Blake J; Marsh DC; Sproule B; Jeyapalan R; Li S
    J Addict Dis; 2008; 27(3):37-48. PubMed ID: 18956528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.